CoraLite® Plus 488-conjugated Caveolin-1 Monoclonal antibody

• 

  IF Staining of human skin cancer using CL488-66067

  Immunofluorescent analysis of (4% PFA) fixed human skin cancer tissue using CL488-66067 (Caveolin-1 antibody) at dilution of 1:100.

• 

  IF Staining of human liver cancer using CL488-66067

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using CoraLite® Plus 488 Caveolin-1 antibody (CL488-66067, Clone: 6C2B2 ) at dilution of 1:200.

• 

  IF Staining of human liver cancer using CL488-66067

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using CL488-66067 (Caveolin-1 antibody) at dilution of 1:100.

• 

  IF Staining of human liver cancer using CL488-66067

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using CL488-66067 (Caveolin-1 antibody) at dilution of 1:100.

• 

  IF Staining of human liver cancer using CL488-66067

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using CL488-66067 (Caveolin-1 antibody) at dilution of 1:100.

• 

  IF Staining of human liver cancer using CL488-66067

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using CL488-66067 (Caveolin-1 antibody) at dilution of 1:100.

• 

  FC experiment of HeLa using CL488-66067

  1X10^6 HeLa cells were intracellularly stained with 0.4 ug CoraLite® Plus 488 Anti-Human Caveolin-1 (CL488-66067, Clone:6C2B2) (red), or 0.4 ug Mouse IgG1 Isotype Control (CL488-66360, Clone: T1F8D3F10) (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

• Featured Product
• KD/KO Validated

Caveolin-1 Monoclonal Antibody for IF-P, FC (Intra)

Cat No. CL488-66067

Clone No.6C2B2

Publications(1)

Host / Isotype

Mouse / IgG1

Reactivity

human, mouse, rat, pig

Applications

IF-P, FC (Intra)

Synonyms

Caveolin 1, CAV1, CGL3, CAV, BSCL3

---

Tested Applications

• Positive IF-P detected in: human liver cancer tissue, human skin cancer tissue
• Positive FC (Intra) detected in: HeLa cells

Recommended dilution

• Immunofluorescence (IF)-P: IF-P : 1:50-1:500
• Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Published Applications

• IF: See 1 publications below

Product Information

CL488-66067 targets Caveolin-1 in IF-P, FC (Intra) applications and shows reactivity with human, mouse, rat, pig samples.

• Tested Reactivity: human, mouse, rat, pig
• Host / Isotype: Mouse / IgG1
• Class: Monoclonal
• Type: Antibody
• Immunogen: Caveolin-1 fusion protein Ag8049
• Full Name: caveolin 1, caveolae protein, 22kDa
• Calculated Molecular Weight: 22 kDa
• Observed Molecular Weight: 20-25 kDa
• GenBank Accession Number: BC006432
• Gene Symbol: CAV1
• Gene ID (NCBI): 857
• RRID: AB_2883249
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Protein G purification
• UNIPROT ID: Q03135
• Storage Buffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

Caveolin-1 (CAV1), a multifunctional protein, is the main constituent molecule of caveolae and represents a scaffolding molecule for several signaling molecules including epidermal growth factor receptor (PMID: 19641024). Several studies have implicated that a reduced expression of CAV1 was found in cancers including head and neck carcinoma (PMID: 19002186). However, other studies recognize CAV1 as a tumor promoter because CAV1 is overexpressed in various kinds of cancers, especially in oral cancer (PMID: 20558341). Recent study also show that CAV1 is involved in gastric Cancer (PMID: 25339030).

Publications

Species	Application	Title
	IF	Nature; Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer; Authors - Mariluz Soula